Paper31360201
Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages.
Lu D and 6 others. Arch Med Sci, 2019. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages. Papers, record 31360201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31360201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Urotensin II promotes secretion of LTB4 through 5-lipoxygenase via the UT-ROS-Akt pathway in RAW264.7 macrophages.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11884288 | Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. | Arterioscler Thromb Vasc Biol | 2002 | https://conductscience.org/library/papers/11884288 | PubMed |
| 2 | 14702425 | Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. | N Engl J Med | 2004 | https://conductscience.org/library/papers/14702425 | PubMed |
| 3 | 15322539 | The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. | Nat Med | 2004 | https://conductscience.org/library/papers/15322539 | PubMed |
| 4 | 15618545 | Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. | Arterioscler Thromb Vasc Biol | 2005 | https://conductscience.org/library/papers/15618545 | PubMed |
| 5 | 16041318 | Leukotriene modifiers as potential therapeutics for cardiovascular disease. | Nat Rev Drug Discov | 2005 | https://conductscience.org/library/papers/16041318 | PubMed |
| 6 | 16172428 | Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. | Hypertension | 2005 | https://conductscience.org/library/papers/16172428 | PubMed |
| 7 | 16343502 | Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. | Atherosclerosis | 2006 | https://conductscience.org/library/papers/16343502 | PubMed |
| 8 | 17261470 | Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. | Am J Hypertens | 2007 | https://conductscience.org/library/papers/17261470 | PubMed |
| 9 | 17617581 | Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. | J Immunol | 2007 | https://conductscience.org/library/papers/17617581 | PubMed |
| 10 | 17761955 | NADPH oxidase deficiency results in reduced alveolar macrophage 5-lipoxygenase expression and decreased leukotriene synthesis. | J Leukoc Biol | 2007 | https://conductscience.org/library/papers/17761955 | PubMed |
| 11 | 18039117 | Inflammation and atherosclerosis. | Annu Rev Pathol | 2006 | https://conductscience.org/library/papers/18039117 | PubMed |
| 12 | 18338983 | Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. | Clin Sci (Lond) | 2008 | https://conductscience.org/library/papers/18338983 | PubMed |
| 13 | 19199921 | Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. | Curr Med Chem | 2009 | https://conductscience.org/library/papers/19199921 | PubMed |
| 14 | 20093252 | The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. | Cardiovasc Res | 2010 | https://conductscience.org/library/papers/20093252 | PubMed |
| 15 | 20416349 | Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway. | Peptides | 2010 | https://conductscience.org/library/papers/20416349 | PubMed |
| 16 | 20554538 | HNE-induced 5-LO expression is regulated by NF-{kappa}B/ERK and Sp1/p38 MAPK pathways via EGF receptor in murine macrophages. | Cardiovasc Res | 2010 | https://conductscience.org/library/papers/20554538 | PubMed |
| 17 | 21691142 | 5-(4-Hydroxy-2,3,5-trimethylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion. | Exp Mol Med | 2011 | https://conductscience.org/library/papers/21691142 | PubMed |
| 18 | 22380002 | Regulation of gene expression in atherosclerosis: insights from microarray studies in monocytes/macrophages. | Pharmacogenomics | 2012 | https://conductscience.org/library/papers/22380002 | PubMed |
| 19 | 22956414 | Evolving concepts of oxidative stress and reactive oxygen species in cardiovascular disease. | Curr Atheroscler Rep | 2012 | https://conductscience.org/library/papers/22956414 | PubMed |
| 20 | 23053343 | Urotensin II promotes the production of LTC4 in rat aortic adventitial fibroblasts through NF-κB-5-LO pathway by p38 MAPK and ERK activations. | Heart Vessels | 2013 | https://conductscience.org/library/papers/23053343 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42410254 | Capsanthin Attenuates Osteoporosis by Targeting the Urotensin II Receptor Pathway to Inhibit Oxidative Stress and NLRP3 Inflammasome Activation. | Calcif Tissue Int | 2026 | https://conductscience.org/library/papers/42410254 | PubMed |
| 42305333 | The impact of diffuse large B-cell lymphoma-derived exosomes on macrophage polarisation and cytokine release. | Arch Med Sci | 2026 | https://conductscience.org/library/papers/42305333 | PubMed |
| 40707413 | Urotensin II system contributes to ischemic acute kidney injury in neonatal pigs. | Ren Fail | 2025 | https://conductscience.org/library/papers/40707413 | PubMed |
| 39596935 | Elevated Urotensin-II and TGF-β Levels in COPD: Biomarkers of Fibrosis and Airway Remodeling in Smokers. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/39596935 | PubMed |
| 39341842 | The urotensin II receptor triggers an early meningeal response and a delayed macrophage-dependent vasospasm after subarachnoid hemorrhage in male mice. | Nat Commun | 2024 | https://conductscience.org/library/papers/39341842 | PubMed |
| 39050164 | Network analysis of the effects of long non-coding RNAs in artemisinin treatment of atherosclerosis in APOE-/- mice. | Arch Med Sci | 2024 | https://conductscience.org/library/papers/39050164 | PubMed |
| 36835230 | Urotensin II Enhances Advanced Aortic Atherosclerosis Formation and Delays Plaque Regression in Hyperlipidemic Rabbits. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36835230 | PubMed |
| 36518054 | Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-α induced by urotensin II. | J Zhejiang Univ Sci B | 2022 | https://conductscience.org/library/papers/36518054 | PubMed |
| 36188724 | Urotensin II level is elevated in inflammatory bowel disease patients. | World J Gastroenterol | 2022 | https://conductscience.org/library/papers/36188724 | PubMed |
| 35174439 | The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions. | J Cell Commun Signal | 2022 | https://conductscience.org/library/papers/35174439 | PubMed |
| 33732368 | Salidroside and isorhamnetin attenuate urotensin II-induced inflammatory response in vivo and in vitro: Involvement in regulating the RhoA/ROCK II pathway. | Oncol Lett | 2021 | https://conductscience.org/library/papers/33732368 | PubMed |
| 32362652 | Oridonin Alleviates IRI-Induced Kidney Injury by Inhibiting Inflammatory Response of Macrophages via AKT-Related Pathways. | Med Sci Monit | 2020 | https://conductscience.org/library/papers/32362652 | PubMed |
| 31754613 | Tanshinone IIA attenuates Aβ-induced neurotoxicity by down-regulating COX-2 expression and PGE2 synthesis via inactivation of NF-κB pathway in SH-SY5Y cells. | J Biol Res (Thessalon) | 2019 | https://conductscience.org/library/papers/31754613 | PubMed |
| 31520306 | Early and Sustained Increases in Leukotriene B4 Levels Are Associated with Poor Clinical Outcome in Ischemic Stroke Patients. | Neurotherapeutics | 2020 | https://conductscience.org/library/papers/31520306 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| UTS2 | 10911 | PubTator's text mining | https://conductscience.org/library/genes/10911 | NCBI Gene |
| UTS2R | 2837 | PubTator's text mining | https://conductscience.org/library/genes/2837 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31360201
GET https://conductscience.org/api/papers/v1/31360201/references?page=2